May 12, 2026 · PDUFA decision
REPL PDUFA decision: a positive outcome, +9.4%
On May 12, 2026, RP1 — Replimune Group, Inc. (Non-Small Cell Lung Cancer (NSCLC)) reached its PDUFA decision. The result was a positive outcome, and the stock moved +9.4% in the window around the event. It had already run -14.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$3.74
1d before
$4.09
Event day
$5.30
1d after
$5.22
5d after
Pre-catalyst setup
-14.5%
30-day run-up
20186%
30-day volatility
0.7×
volume spike